BRIEF—Tetraphase foursquare behind Xerava

Tetraphase Pharmaceuticals has announced a corporate reorganization, “in order to maximize the commercial opportunity for Xerava (eravacycline),” an antibacterial  approved by the US regulator in August 2018.

The firm will eliminate its internal research and look to out-license its pipeline to focus solely on the commercial success of Xerava. This is expected to save up to $8 million per year.

Tetraphase has also promoted Larry Edwards, currently chief operating officer, to become the new chief executive officer and Maria Stahl, currently a senior VP, to become chief business officer.